Category Archives: Myocardial Infarction

Global Myocardial Infarction Therapeutics Insights, Forecast to 2027Myocardial Infarction Therapeutics market report focuses on the COVID19 Outbreak Impact analysis of key points susceptible to market growth. PESTEL analysis, Five Force analysis, and SWOT analysis are used by our research team to depict the market Risk Analysis, trade chain, development trends, competitive landscape analysis, and key regions development status. Holistic market research is conducted by analysts to understand product persona, market segmentation, changing technological aspects, market news, acquisition, and various company profiles that provide accurate and applicable data to the readers, stakeholders, and industry experts. Continue reading →

This article was originally published here Am J Med. Continue reading →

This article was originally published here Curr Cardiol Rep. 2021 May 7;23(6):69. doi: 10.1007/s11886-021-01501-7. Continue reading →

Patients suffering a heart attack received percutaneous coronary intervention (PCI), a procedure to clear blocked arteries in the heart, an average of 10 minutes faster after clinicians and paramedics began using an app to facilitate efficient hospital intakes for these patients, according to a study being presented at the American College of Cardiologys 70th Annual Scientific Session. The study was conducted at Baystate Medical Center, a health system headquartered in Springfield, Massachusetts, that, like many U.S. Continue reading →

The report on Myocardial Infarction Drug market intent to make the readers aware about the latest development in this business sphere, including Covid-19 aftermath, to aid in informed decision making. The highly detailed Myocardial Infarction Drug market research report predicts the future behaviour of this business sphere through expert opinions on the past and current industry development data. It highlights the key growth markers, opportunities, as well as the restraints existing in the marketplace Continue reading →

REDWOOD CITY, Calif. & NEPTUNE BEACH, Fla.--(BUSINESS WIRE)--HeartFlow, Inc., a leader in revolutionizing precision heartcare, and MedAxiom, an American College of Cardiology (ACC) company whose mission is to transform cardiovascular care and improve heart health, announced today a collaboration to improve cardiovascular care for patients with coronary artery disease (CAD). The collaboration will focus on increasing awareness among providers and payors about the coronary computed tomography angiography (CTA) and HeartFlow FFRct Analysis diagnostic pathway, and equipping practitioners with the tools they need to best adapt their practices to utilize CTA more broadly Continue reading →

A new study found that a restrictive blood transfusion strategy had comparable outcomes to a liberal transfusion strategy in patients with acute myocardial infarction and anemia. Continue reading →

Healed myocardial infarction is common among people who suffer sudden death, far outnumbering acute MI, Norwegian autopsy data show. Continue reading →

Coronary artery disease, or heart disease, is caused by atherosclerosis, a process which involves the accumulation of cholesterol plaques in the arteries that supply blood to the heart. These plaques can narrow the blood vessels and reduce blood and oxygen delivery to the heart (called ischemia), leading to symptoms like chest pain. Continue reading →

The global stem therapy market growth will be driven by extensive R&D activities aimed at developing novel therapies and personalized medicines. For example, to treat patients who have suffered a myocardial infarction (heart attack), scientists are emphasizing on developing techniques to regenerate healthy heart from placental stem cells. As per the Centers for Disease Control and Prevention (CDC), heart diseases in the U.S. Continue reading →